Brief: Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement For Clinical Research And Development
04/05/2023 14:11
May 4 (Reuters) - Optimi Health Corp OPTI.CD :
* OPTIMI HEALTH ANNOUNCES CAD$1.2 MILLION GMP PSILOCYBIN
SUPPLY
AGREEMENT FOR CLINICAL RESEARCH AND DEVELOPMENT
Source text for Eikon: ID:nGNX3FFYcX
Further company coverage: OPTI.CD
Recent news on Optimi Health
See all newsExplainer: As Trump backs psychedelics research, FDA weighs safety and access standards
Brief: Optimi Health Corp - Trial Initiation Planned For H1 2027, Dosing To Complete By End Of 2027
Brief: Optimi Health Offers 2.4 MLn Common Shares At A Public Offering Price Of US$6.25 Per Share
Brief: Optimi Health Corp Now Sees IPO Of 2.4 Million Common Shares
Trump's psychedelic drug order boosts investor interest with promise of faster reviews